- NCIt
- C40099
Loading cancer entity…
Loading cancer entity…
Clinical trials
47 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02713386 | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 147 | NRG OncologyOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT02898207 | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 26, 2023 | clinicaltrials |
| NCT01074411 | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2019 | clinicaltrials |
Data updated 22 days agoSource updated May 25, 2025source: clinicaltrials